Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016 | BMC Cancer | Full Text

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016 | BMC Cancer | Full Text

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physi...

Authors:Thomas M. Schwedhelm, Judy R. Rees, Tracy Onega, Ronnie J. Zipkin, Andrew Schaefer, Maria O. Celaya and Erika L. Moen

Citation:BMC Cancer 2020 20:847

Content type:Research article

 

Published on: 3 September 2020

• ViewFull Text
 
• ViewPDF